

CONTENTS

<i>Preface</i>	(v)
<i>Contributors</i>	(vii)

Chapter – 1

Spherical Crystallization in Solubility Enhancement

1.1 Introduction	1
1.2 Mechanism of Solubility	3
1.3 Factors Influencing Solubility of Drugs	4
1.4 Spherical Crystallization	7
1.5 Methods of Spherical Crystallization	20
1.5.1 Spherical Agglomeration Method (SA)	21
1.5.2 Emulsion Solvent Diffusion (ESD)	21
1.5.3 Ammonia Diffusion Method (ADM)	21
1.5.4 Neutralization Method (NT)	23
1.5.5 Traditional Crystallization Process (TCP)	23
1.6 The Principle Steps Involved in the Process of Spherical Crystallization	23
1.6.1 Flocculation Zone	23
1.6.2 Zero Growth Zone	24
1.6.3 Fast Growth Zone	24
1.6.4 Constant Size Zone	25
1.7 Factors Controlling the Process of Agglomeration (Kulkarni et al., 2002)	25
1.7.1 Solubility Profile	25
1.7.2 Mode and Intensity of Agitation	25
1.7.3 Temperature of the System	26
1.7.4 Residence Time	26
1.8 Applications of Spherical Crystallization in Solubility Enhancement in Pharmaceuticals	26
1.9 Case Study	27
1.10 Conclusion	33
<i>References</i>	33

Chapter – 2

**Self Emulsifying Drug Delivery System (SEDDS)
and Self-Microemulsifying Drug Delivery System
(SMEDDS)**

2.1	Introduction	42
2.2	Types of Emulsions	43
2.3	Microemulsions	44
2.3.1	Microemulsions are not Nanoemulsions.....	44
2.3.2	Mechanism of Forming Microemulsions.....	45
2.3.3	The Applications of Microemulsions.....	46
2.3.4	Phase Inversion in Microemulsions	47
2.3.5	Drug Absorption, Distribution, Metabolism and Excretion after Oral Administration [Graham JDP et al.]	47
2.4	Self Emulsifying Drug Delivery Systems (SEDDS).....	48
2.5	Self Microemulsifying Drug Delivery Systems (SMEDDS) ..	50
2.6	Drug Capacity in Microemulsions	51
2.6.1	Mechanism of Enhancement of Drugs Absorption in SMEDDS	52
2.6.2	Factors Influencing the Bioavailability of Self-Microemulsifying	52
2.7	Applications of SMEDDS and the Challenges.....	53
2.8	Advantages of SEDDS and SMEDDS	54
2.9	Limitations of SEDDS	54
2.10	Composition of Self-Emulsifying Process	54
2.11	Formulation of SEDDS	54
2.11.1	Mechanism of Self-Emulsification	55
2.11.2	Various Terminologies	59
2.11.3	Advantages of Self Emulsifying Drug Delivery System (SEDDS)	59
2.11.4	Drawbacks of SEDDS	60
2.11.5	Similarity between SEDDS and SMEDDS.....	60
2.11.6	Screening of Excipients for SEDDS	60
2.12	Composition of Self Emulsification Process.....	61
2.13	Techniques of Solid SEDDS Development.....	62

2.14	Dosage Forms from Self Emulsifying System	63
2.15	Toxicity and Safety of SMEDDS	64
2.16	Applications of SEDDS	65
2.17	Factors Affecting SEDDS	66
2.17.1	Polarity of the Lipophilic Phase	66
2.17.2	Nature and Dose of the Drug	66
2.17.3	Improvement in Solubility and Bioavailability	67
2.17.4	Protection against Biodegradation	67
2.18	Characterization	68
2.18.1	Visual Assessment	68
2.18.2	Thermodynamic Stability Studies	68
2.18.3	Dispersibility Test	69
2.18.4	Turbidimetric Evaluation	69
2.18.5	Viscosity Determination	69
2.18.6	Droplet Size Analysis and Particle Size Measurements	70
2.18.7	Zeta Potential Measurement	70
2.18.8	Refractive Index and Percentage Transmittance	70
2.18.9	Electro Conductivity Study	70
2.18.10	<i>In-vitro</i> Diffusion Study	70
2.18.11	Drug Content	71
2.18.12	Biopharmaceutical Aspects	71
2.18.13	Alterations (Reduction) in Gastric Transit	71
2.18.14	Increases in Effective Luminal Drug Solubility	71
2.18.15	Stimulation of Intestinal Lymphatic Transport	71
2.18.16	Changes in the Biochemical Barrier Function of the GI Tract	71
2.18.17	Changes in the Physical Barrier Function of the GI Tract	72
2.19	Conclusion	72
	<i>References</i>	72

Chapter – 3

Taste Masking

3.1	Introduction	81
3.2	Mechanism of Taste Perception by Receptor Cell	82

(xiv) *Contents*

3.3 Taste Masking Techniques.....	83
3.4 Sensory Evaluation.....	100
<i>References</i>	102

Chapter – 4

Ocular Drug Delivery System

4.1 Introduction	111
4.1.1 Advantages of Controlled Ocular Drug Delivery Systems.....	113
4.1.2 Mechanism of Controlled/Sustained Drug Release into the Eye	114
4.1.3 Eye Background.....	114
4.1.3.1 Eye Structure.....	114
4.1.4 Ocular Surface Disorders.....	117
4.1.5 Ocular Drug Delivery Considerations	119
4.1.5.1 Anatomical and Physiological Considerations	119
4.1.6 Ocular Barriers and Membranes	120
4.1.6.1 Tear Film.....	121
4.1.6.2 Corneal and Non-Corneal Routes of Absorption	121
4.1.6.3 Blood-Ocular Barriers.....	122
4.1.6.4 Blood-Aqueous Barrier.....	122
4.1.6.5 Blood-Retinal Barrier (BRB).....	122
4.1.6.6 Mechanisms of Transport	123
4.1.6.7 Ocular Membrane Transport Machineries.....	123
4.1.6.8 Influx and Efflux Transporters.....	123
4.1.6.9 Endocytosis and Transcytosis	124
4.1.6.10 Routes Transport.....	124
4.1.7 Drug Transporters	126
4.1.7.1 Cornea.....	127
4.1.8 Pharmacokinetic Considerations.....	129
4.1.8.1 Formulation Considerations.....	131
4.1.9 Formulation Approaches to Improve Ocular Drug Delivery	133
4.1.9.1 Conventional Delivery Systems.....	133
4.1.9.2 Colloidal Delivery Systems	138

4.1.9.3	Micro Emulsions.....	138
4.1.9.4	Polymeric Nanoparticles.....	140
4.1.9.5	Implants	142
4.1.10	New Ophthalmic Drug Delivery System (NODDS).....	151
4.1.11	Advanced Delivery Systems.....	152
4.1.11.1	Gene Therapy.....	153
4.1.11.2	Stem Cell Therapy	153
4.1.11.3	Protein and Peptide Therapy.....	153
4.1.11.4	Scleral Plug Therapy.....	154
4.1.11.5	siRNA Therapy	154
4.1.11.6	Oligonucleotide Therapy	155
4.1.11.7	Aptamer	155
4.1.11.8	Ribozyme Therapy.....	155
4.1.12	Evaluation of Ocular Drug Delivery Systems.....	156
	<i>References</i>	165

Chapter – 5

Prodrug: An Approach to Drug Delivery

5.1	Introduction	183
5.2	Classification of Prodrugs	186
5.3	The Role of Chemistry in Prodrug Derivatization	187
5.4	Principle of Drug Release in Prodrug Therapy	189
5.5	Applications of Prodrugs.....	192
	<i>References</i>	219

Chapter – 6

Expandable Drug Delivery Systems

6.1	Introduction.....	235
6.2	Physiological Considerations	237
6.2.1	Gastric pH.....	238
6.2.2	Requirements for Gastric Retention.....	242
6.3	Drug Candidates for Gastric Retention	242
6.4	Factors Affecting Gastric Retention	
	Time of the Dosage Form.....	242
6.4.1	Physiological Factors.....	242
6.4.2	Biological Factors.....	243

6.5 GRDDS Technologies.....	244
6.5.1 Size Increasing Systems.....	244
References	266

Chapter – 7

Nanosuspensions

7.1 Introduction.....	270
7.2 Advantages of Nanosuspensions.....	271
7.3 Formulation Considerations	274
7.4 Production of Nanosuspensions	275
7.5 Surface Modification of Nanosuspensions.....	280
7.6 Properties of Nanosuspensions.....	281
7.7 Applications of Nanosuspensions	284
7.7.1 Oral Drug Delivery	284
7.7.2 Ocular Drug Delivery	286
7.7.3 Pulmonary Drug Delivery.....	287
7.7.4 Targeted Drug Delivery	288
7.7.5 Parenteral Drug Delivery	289
References	302

Chapter – 8

Lozenges

8.1 Introduction.....	308
8.2 Advantages [Vikas Jain et al, Lieberman HA, Lachman L].....	308
8.3 Disadvantages [Vikas Jain et al, Lieberman HA, Lachman L]	309
8.4 Sugar Candy Lozenges [Lieberman HA, Lachman L, Candy - Wikipedia].....	310
8.4.1 Ingredients [Confectionery Acques Michaud Cerestar].....	310
8.4.2 Corn Syrup.....	311
8.4.2.1 Dextrose Equivalent.....	312
8.4.2.2 Applications.....	313
8.4.3 Mechanism of Inhibition of Crystallization.....	314
8.4.4 Manufacturing [Lieberman HA, Lachman L, Candy - Wikipedia].....	314

8.5 Stages of Sugar Cooking are as follows.....	316
8.6 Flavouring [Lloyd V. Allen, JR., Secundum Artem, Lieberman HA and Lachman].....	317
8.7 Preservatives [Lloyd V. Allen, Jr., Secundum Artem, Lieberman HA, Lachman L	320
8.8 Hard Candy Graining, Causes and Prevention.....	321
8.8.1 Controlling Ingredients of Graining.....	321
8.8.2 Causes for Graining	322
8.9 Type of Equipment.....	323
8.10 Calibration of Mould with Example of Calculation.....	325
8.10.1 Calculation for Batch Compounding	325
8.11 Hard Candy Processing Problems and Solution.....	326
8.11.1 Problems related to Appearance	326
8.12 Problems Related to Eating Quality	329
8.13 Compressed Tablet Lozenges [Lieberman HA, Lachman L, Rajesh Kini et al, Nagoba, et al]	331
8.13.1 Ingredients [Lieberman HA, Lachman L, Genral lozenges consideration Chapter 7a]	333
8.14 Soft Lozenges [Lieberman HA, Lachman L, Lloyd V. Allen, Jr., Secundum Artem]	334
8.15 Chewable Lozenges [pharmlabs.unc.edu,].....	335
8.16 Packaging	336
8.17 Storage.....	336
8.18 Dispensing.....	336
8.19 Quality Control of Lozenges [Lieberman HA, Lachman L, Vikas Jain Nagoba, et al]	336
<i>References</i>	341

Chapter – 9

Ungual Drug Delivery

9.1 Introduction	343
9.1.1 Structure of Human Nail.....	343
9.1.2 Parts of the Nail	343
9.2 Functions of Nail.....	346
9.3 Permeability	346
9.4 Growth.....	346

(xviii) Contents

9.5 Diseases Affecting the Nail.....	347
9.5.1 Definition.....	347
9.5.2 Distal and Lateral Subungual Onychomycosis (DLSO).....	348
9.5.3 Superficial White Onychomycosis (SWO).....	348
9.5.4 Proximal Subungual Onychomycosis (PSO).....	349
9.5.5 Candidal Onychomycosis.....	349
9.5.6 Total Dystrophic Onychomycosis.....	350
9.6 Diagnosis.....	350
9.7 Treatment.....	350
9.7.1 Limitations of the Current Treatment Methods ...	351
9.7.2 Advantages of Topical Therapy.....	351
9.8 Factors Affecting Transungual Drug Permeation.....	352
9.9 Methods to Enhance Transungual Drug Permeation.....	353
9.9.1 Chemical Enhancement of Transungual Drug Delivery.....	353
9.9.2 Physical Methods used to Enhance the Transungual Permeation.....	354
9.10 Gels.....	355
9.11 Preformulation Studies (Leon, Martin).....	360
9.11.1 Drug-excipient Compatibility Studies.....	360
9.11.2 Analytical Method used in the Determination of Pure Drug.....	361
9.11.3 Preparation of Standard Graph.....	361
9.12 Method for Determination of Minimum Inhibitory Concentration.....	361
9.13 Formulation and Evaluation of Antifungal Nail Gel.....	363
9.13.1 Formulation Design.....	363
9.13.2 General Formulation.....	363
9.13.3 Procedure.....	363
9.13.4 Evaluation of Nail Gel Formulations.....	363
9.13.5 <i>In Vitro</i> Release Studies (Nail Permeation Studies).....	367
<i>References</i>	368

Chapter – 10

Optimization Techniques in Product Development

10.1	Introduction	375
10.2	Terminology used in DoE	376
10.2.1	Independent Variables	376
10.2.2	Dependent Variables	376
10.2.3	Coding.....	376
10.2.4	Effect.....	377
10.2.5	Blocking.....	378
10.2.6	Design Augmentation	378
10.2.7	Resolution	378
10.2.8	Power of the Design.....	379
10.3	DoE: Fundamental Aspects	380
10.4	One Factor at a Time (OFAT).....	381
10.5	Designs for Experimentation.....	382
10.5.1	Factorial Designs	383
10.5.2	Fractional Factorial Design.....	385
10.5.3	Plackett–Burman Designs.....	385
10.5.4	Central Composite Design.....	386
10.5.5	Box-Behnken Design	388
10.5.6	Center of Gravity Designs	390
10.5.7	Doehlert Design	390
10.5.8	Mixture Designs.....	390
10.5.9	Taguchi Designs	393
10.5.10	Optimal Designs	395
10.6	Selection of Experimental Designs	395
10.7	Execution of Design	396
10.8	Modeling of Data	396
10.9	Selection of the Model	397
10.10	Calculation of the Coefficients from Polynomial Equations	397
10.11	Estimation of the Significance of Coefficients and Model	398
10.12	Adequate Precision.....	399
10.13	Model Diagnostic Plots	399
10.13.1	Actual vs. Predicted	399

(xx) *Contents*

10.13.2	Residuals vs. Predicted	400
10.13.3	Residuals vs. Factor	400
10.13.4	Residuals vs. Run.....	400
10.13.5	Normal Probability Plot.....	400
10.13.6	Tests for Outlier Detection.....	400
10.13.7	Box-Cox Plot for Power Transforms	402
10.14	Search for Optimum	403
10.14.1	Numerical Optimization	403
10.14.2	Graphical Optimization.....	404
10.14.3	Optimization by Extrapolation.....	407
10.15	Validation of Optimization Methodology	408
10.16	Applications of DoE.....	408
10.17	Conclusions	410
10.18	Case Study.....	410
10.18.1	Selection Criteria for the Drug.....	410
10.18.2	Preparation of Reservoir-Based TTS	411
10.18.3	Experimental Design.....	411
10.18.4	<i>Ex-vivo</i> Permeation Studies	412
10.18.5	Check Point Analysis and Optimization Model Validation	413
10.18.6	Results and Discussion	413
10.18.6.1	Formulation Optimization by Experimental Design.....	413
10.18.6.2	Fitting of Data to the Model.....	414
10.18.6.3	Data Analysis.....	414
10.18.6.4	Optimization	415
10.18.6.5	Conclusions.....	415
	<i>References</i>	415